× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.


meta|Evidence - COVID-19

Living meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En     Fr

Our approach
   
insufficient data

Interactive explorer of NMA results

1NIH NIAID ACTT-1, 2020Risk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcorticosteroidsRisk of bias: - high: 0.0 % - some concerns: 100.0 % - low: 0.0 % - NA: 0.0 %remdesivirRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNconvalescent plasma treatmentRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNbaricitinibRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNtofacitinibRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcasirivimab/imdevimab (Ronapreve)Risk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNinterferonRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNtocilizumab Risk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNsarilumabRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcontroldirect evidencenetwork meta-analysis ROB:highsome concernslowNA

Click on treatment name to display related network evidence

T vs. C corticosteroidsremdesivirconvalescent plasma treatmentbaricitinibtofacitinibcasirivimab/imdevimab (Ronapreve)interferontocilizumab sarilumabcontrol
corticosteroids---NANANANANANANANANA
remdesivirNA---NANANANANANANANA
convalescent plasma treatmentNANA---NANANANANANANA
baricitinibNANANA---NANANANANANA
tofacitinibNANANANA---NANANANANA
casirivimab/imdevimab (Ronapreve)NANANANANA---NANANANA
interferonNANANANANANA---NANANA
tocilizumab NANANANANANANA---NANA
sarilumabNANANANANANANANA---NA
controlNANANANANANANANANA---

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons